143017-63-4Relevant articles and documents
BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder
Marcin, Lawrence R.,Warrier, Jayakumar,Thangathirupathy, Srinivasan,Shi, Jianliang,Karageorge, George N.,Pearce, Bradley C.,Ng, Alicia,Park, Hyunsoo,Kempson, James,Li, Jianqing,Zhang, Huiping,Mathur, Arvind,Reddy, Aliphedi B.,Nagaraju,Tonukunuru, Gopikishan,Gupta, Grandhi V. R. K. M.,Kamble, Manjunatha,Mannoori, Raju,Cheruku, Srinivas,Jogi, Srinivas,Gulia, Jyoti,Bastia, Tanmaya,Sanmathi, Charulatha,Aher, Jayant,Kallem, Rajareddy,Srikumar, Bettadapura N.,Vijaya, Kumar Kuchibhotla,Naidu, Pattipati S.,Paschapur, Mahesh,Kalidindi, Narasimharaju,Vikramadithyan, Reeba,Ramarao, Manjunath,Denton, Rex,Molski, Thaddeus,Shields, Eric,Subramanian, Murali,Zhuo, Xiaoliang,Nophsker, Michelle,Simmermacher, Jean,Sinz, Michael,Albright, Charlie,Bristow, Linda J.,Islam, Imadul,Bronson, Joanne J.,Olson, Richard E.,King, Dalton,Thompson, Lorin A.,Macor, John E.
, p. 472 - 477 (2018/05/23)
There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the N-methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We
Selective NR2B Antagonists
-
, (2015/07/15)
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the c
